Skip to main content

BiondVax Pharmaceuticals Ltd. (BVXV)

NASDAQ: BVXV · IEX Real-Time Price · USD
2.34 -0.09 (-3.70%)
Sep 20, 2021 10:23 AM EDT - Market open
Market Cap34.83M
Revenue (ttm)n/a
Net Income (ttm)6.47M
Shares Out14.33M
EPS (ttm)-2.30
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume30,108
Open2.28
Previous Close2.43
Day's Range2.25 - 2.37
52-Week Range2.10 - 43.57
Beta2.28
Analystsn/a
Price Target81.00 (+3,361.5%)
Est. Earnings Daten/a

About BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and related illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

IndustryPharmaceuticals
Founded2003
CEORon Babecoff
Employees21
Stock ExchangeNASDAQ
Ticker SymbolBVXV
Full Company Profile

Financial Performance

Financial numbers in millions ILSFinancial Statements

News

BiondVax Announces Second Quarter 2021 Financial Results and Provides Business Update

JERUSALEM, Aug. 26, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

3 weeks ago - PRNewsWire

BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update

JERUSALEM, June 23, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

2 months ago - PRNewsWire

BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

JERUSALEM, May 13, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pre...

4 months ago - PRNewsWire

Letter from BiondVax's New CEO to Shareholders

JERUSALEM, March 23, 2021 /PRNewswire/ -- Dear Shareholders, After many years of pharmaceutical leadership positions in the US and Europe, I jumped at the opportunity to return to my roots in Israel to ...

5 months ago - PRNewsWire

BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering

JERUSALEM, Feb. 10, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

7 months ago - PRNewsWire

BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering

JERUSALEM, Israel, Feb. 2, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for...

7 months ago - PRNewsWire

BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares

JERUSALEM, Jan. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

7 months ago - PRNewsWire

BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

7 months ago - PRNewsWire

BiondVax Announces Third Quarter 2020 Financial Results & Business Update

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

7 months ago - PRNewsWire

BiondVax Announces Appointment of Amir Reichman as New CEO

JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment o...

7 months ago - PRNewsWire

Why BiondVax Pharmaceuticals Stock Imploded Today

The company reported negative results from a pivotal clinical trial.

10 months ago - The Motley Fool

Why BiondVax Pharma Is Getting Absolutely Crushed

BlondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) was absolutely crushed on Friday after the company reported late-stage results from its flu vaccine study.

10 months ago - 24/7 Wall Street

BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate

JERUSALEM, Oct. 23, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, sea...

10 months ago - PRNewsWire

BiondVax Announces At-The-Market (ATM) Equity Offering Program

JERUSALEM, Israel, Oct. 2, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate ("BiondVax" or the "Comp...

11 months ago - PRNewsWire

BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company

BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company

1 year ago - Seeking Alpha

BiondVax Announces Second Quarter 2020 Financial Results

JERUSALEM, Aug. 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

1 year ago - PRNewsWire

Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical ...

JERUSALEM, July 1, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial o...

1 year ago - PRNewsWire

BiondVax Announces First Quarter 2020 Financial Results

JERUSALEM, June 30, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza v...

1 year ago - PRNewsWire

BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

JERUSALEM, June 12, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza v...

1 year ago - PRNewsWire

NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary...

JERUSALEM, June 10, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced the completion of the clinical study report (CSR) of a Phase 2 clinical trial of the Company's M-001...

1 year ago - PRNewsWire

BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants

JERUSALEM, May 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M‑001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $...

1 year ago - PRNewsWire